Animal Data Suggest Serotonin Receptor Antagonist Cyproheptadine May Block Post-MI Valve Remodeling

Join our community to access additional content!

CRT Community

$0.00

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Join Now!
Already have an account? Login Now

CRT Community Premium

$650 Annually

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Complimentary subscription to electronic version of the CRM Journal

Access to CRT Meeting Registration Discounts

CRT Premium Content, including on-demand videos and presentation downloads

Join Now!
Already have an account? Login Now
News

Animal Data Suggest Serotonin Receptor Antagonist Cyproheptadine May Block Post-MI Valve Remodeling

Posted: 07/25/2022
Author:
Nathan Gray, CRTonline.org
News Articles 2022 ACS & AMI

The 5-hydroxytryptamine (5-HT: or serotonin) type 2B receptor (5-HT2BR) antagonist cyproheptadine reduces 5-HT levels after myocardial infarction (MI), prevents valvular fibrotic remodeling, and is associated with a larger increase in mitral valve size and less mitral regurgitation (MR), new lab and animal data suggest.

Most Viewed Pages

Exercise Can Change Your Mind: Physical Activity’s CVD Benefits Linked to Stress-Related Neural Pathways

First-in-Human Percutaneous Removal of Left Atrial Appendage Occlusion Devices With a Novel Retrieval System

First-in-Human Percutaneous Removal of Left Atrial Appendage Occlusion Devices With a Novel Retrieval System

Preventative PCI with Optimal Medical Therapy Reduces Long-Term MACE in Patients with Non-Flow-Limiting Vulnerable Plaques: PREVENT Trial

Exercise, Protein Supplementation Improve Physical Functioning in Older, Frail Patients Undergoing TAVR: Trial

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Join our community to access additional content!

CRT Community

CRT Community Premium

News

Animal Data Suggest Serotonin Receptor Antagonist Cyproheptadine May Block Post-MI Valve Remodeling

Most Viewed Pages

Explore the Site

Stay Connected